Asymptotic analysis of the Navier-Stokes equations in a curved domain with a non-characteristic boundary

We consider the Navier-Stokes equations of an incompressible fluid in a three dimensional curved domain with permeable walls in the limit of small viscosity. Using a curvilinear coordinate system, adapted to the boundary, we construct a corrector function at order $\varepsilon^{j}$, $j = 0, 1$, where $\varepsilon$ is the (small) viscosity parameter. This allows us to obtain an asymptotic expansion of the Navier-Stokes solution at order $\varepsilon^{j}$, $j = 0, 1$, for $\varepsilon$ small . Using the asymptotic expansion, we prove that the Navier-Stokes solutions converge, as the viscosity parameter tends to zero, to the corresponding Euler solution in the natural energy norm. This work generalizes earlier results in [14] or [26], which discussed the case of a channel domain, while here the domain is curved

A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer

Introduction: To evaluate the safety profile characteristics of abiraterone acetate (AA) in the treatment of metastatic prostate cancer (mPCa). Areas covered: In this literature review the authors evaluate safety data from phase III trials investigating the combination of abiraterone acetate plus prednisone (AAP) in patients with metastatic prostate cancer. In particular, the aim was to clarify its toxicity profile, long-term exposure impact, and the correlation with general health-related quality of life (HRQoL). Expert opinion: Based on the studies reviewed, it appears that abiraterone acetate has favourable outcomes, is effective and well tolerated, mostly in asymptomatic or slightly symptomatic patients, and has recognised toxicity profile characteristics. Incidence of adverse events (AEs), such as mineralocorticoid- and corticosteroid-releated AEs, and hepatotoxicity is well known and widely described. Understanding the toxicity profile of AA could assist decision-making in clinical practice